Financials Sprint Bioscience AB

Stocks

Market Closed - Nasdaq Stockholm 21:00:00 28/10/2026 +04			5-day change	1st Jan Change
3.440 ^SEK	+0.88%		-0.58%	+134.01%

08-26	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	35.11	0.083	50.48	65.64	167.2	86.8	96.8
Change	-	-99.76%	60,725.3%	30.02%	154.67%	-48.08%	11.52%
EBITDA ¹	-25.04	-60.12	-0.398	-18.71	98.36	26.8	38.5
Change	-	-140.12%	99.34%	-4,601.01%	625.73%	-72.75%	43.66%
EBIT ¹	-25.63	-60.74	-0.845	-19.67	97.29	25.7	37.5
Change	-	-137.01%	98.61%	-2,227.57%	594.67%	-73.58%	45.91%
Interest Paid	-	-	-	-	-5.555	-	-
Earnings before Tax (EBT)	-25.08	-	-	-	-	-	-
Change	-	-	-	-	-	-	-
Net income	-25.08	-	-	-	-	-	-
Change	-	-	-	-	-	-	-
Announcement Date	16/02/22	15/02/23	14/02/24	12/02/25	11/02/26	-	-

¹SEK in Million

Estimates

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027
Net Debt	-70.6	-29.5	-49.9	-25.1	-	-	-
Change	-	58.22%	-69.15%	49.7%	-	-	-
Announcement Date	16/02/22	15/02/23	14/02/24	12/02/25	11/02/26	-	-

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025
CAPEX ¹	-	2.707	-	2.454	1.297	0.094
Change	-	-	-	-	-47.15%	-92.75%
Free Cash Flow (FCF) ¹	-15.17	-23.87	-36.81	19.99	-18.16	52.4
Change	-	-57.32%	-54.23%	154.29%	-190.87%	388.53%
Announcement Date	15/04/21	13/04/22	05/04/23	09/04/24	04/04/25	15/04/26

¹SEK in Million

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-71.3%	-72,436.14%	-0.79%	-28.5%	58.84%	30.88%	39.77%
EBIT Margin (%)	-	-72.99%	-73,180.72%	-1.67%	-29.96%	58.2%	29.61%	38.74%
EBT Margin (%)	-	-71.43%	-	-	-	-	-	-
Net margin (%)	-	-71.43%	-	-	-	-	-	-
FCF margin (%)	-	-121.96%	-71,149.4%	-34.85%	-37.56%	-	-	-
FCF / Net Income (%)	-	170.73%	-	-	-	-	-	-
Profitability
ROA	-89.46%	-28.29%	-65.01%	-1.66%	-22.46%	68.23%	-	-
ROE	-424.5%	-63.02%	-122%	-1.57%	-98.67%	142.84%	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	7.71%	-	4.86%	1.98%	0.06%	-	-
CAPEX / EBITDA (%)	-	-10.81%	-	-616.58%	-6.93%	0.1%	-	-
CAPEX / FCF (%)	-	-6.32%	-	-13.95%	-5.26%	-	-	-
Items per share
Cash flow per share ¹	1.276	1.773	0.4226	0.7152	0.3589	1.201	-	-
Change	-	38.93%	-76.17%	69.25%	-49.82%	234.61%	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	0.431	1.768	0.4039	0.3978	0.1328	1.129	-	-
Change	-	310.25%	-77.16%	-1.5%	-66.62%	750.52%	-	-
EPS ¹	-2.55	-0.8504	-1.431	-0.006274	-0.2618	0.98	-	-
Change	-	66.65%	-68.22%	99.56%	-4,072.33%	474.37%	-	-
Nbr of stocks (in thousands)	21,215	39,844	39,844	69,820	69,820	105,516	-	-
Announcement Date	15/04/21	13/04/22	05/04/23	09/04/24	04/04/25	15/04/26	-	-